Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem

Fineline Cube May 14, 2026
Drug

Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations

Fineline Cube May 14, 2026
Company Drug

Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability

Fineline Cube May 14, 2026
Drug

Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study

Fineline Cube Jul 22, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...

Company Drug

Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC

Fineline Cube Jul 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...

Company Deals

Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang

Fineline Cube Jul 22, 2022

China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...

Company Drug

Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye

Fineline Cube Jul 22, 2022

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity

Fineline Cube Jul 22, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Drug

Sinopep-Allsino Biopharm’s SPN0103-009 Receives NMPA Approval for Diabetes and Obesity Clinical Study

Fineline Cube Jul 22, 2022

China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National...

Drug

Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors

Fineline Cube Jul 22, 2022

The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co.,...

Company Deals

Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base

Fineline Cube Jul 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue...

Company Drug

Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE

Fineline Cube Jul 22, 2022

The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’...

Company

Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics

Fineline Cube Jul 22, 2022

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in...

Company Drug

InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone

Fineline Cube Jul 22, 2022

China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...

Company Deals

Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC

Fineline Cube Jul 21, 2022

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...

Company Deals

MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines

Fineline Cube Jul 21, 2022

MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9...

Company Drug

Livzon’s V-01 and V-01D-351 Vaccines Show Strong Safety, Immunity as COVID Boosters

Fineline Cube Jul 21, 2022

China-based Livzon Pharmaceutical Group (HKG: 1513) released clinical data for its recombinant novel coronavirus fusion...

Drug

CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial

Fineline Cube Jul 21, 2022

China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...

Company Deals

InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018

Fineline Cube Jul 21, 2022

China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt...

Company Deals

Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001

Fineline Cube Jul 21, 2022

Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round,...

Company Drug

DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial

Fineline Cube Jul 20, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...

Company

J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns

Fineline Cube Jul 20, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year...

Company

Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx

Fineline Cube Jul 20, 2022

Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...

Posts pagination

1 … 646 647 648 … 665

Recent updates

  • Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations
  • Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability
  • TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections
  • Kanghong Pharma’s Gene Therapy KHN921 Receives FDA Approval for Hypertrophic Cardiomyopathy Trial – AAV9 Vector Targets MYBPC3 Mutations with Potential One-Time Treatment
  • InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial – Novel Oral IL-17AA/AF Inhibitor Shows Promise for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug

Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations

Company Drug

Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Company Drug

Kanghong Pharma’s Gene Therapy KHN921 Receives FDA Approval for Hypertrophic Cardiomyopathy Trial – AAV9 Vector Targets MYBPC3 Mutations with Potential One-Time Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.